Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Price: $39.56 +0.10%
Rating Summary:
19 Buy, 20 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 31
Rating Summary:
19 Buy, 20 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 6 | New: 31
Join SI Premium – FREE
Morgan Stanley downgraded Teva Pharma (NYSE: TEVA) from Overweight to Equalweight with a price target of $42.00 (from $63.00).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $37.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Teva Pharma (TEVA) at Outperform
- KEPCO (015760:KS) (KEP) PT Lowered to KRW26,000 at JPMorgan
- Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
